Publication | Open Access

Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors

Overall SurvivalMedicinePathologyImmune Checkpoint InhibitorNsclc TreatedCancer TreatmentOncologyRadiation OncologyLung Cancer